Human Metabolome Technologies, Inc.

Equities

6090

JP3794530000

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 01:37:07 2024-04-26 am EDT			5-day change	1st Jan Change
655 ^JPY	-1.06%		-2.38%	+2.34%

Feb. 14	Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2024	CI
2023	Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024	CI

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024

August 10, 2023 at 02:00 am EDT

Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 30, 2024. For the year ending June 30, 2024, the company expects net sales of JPY 1,450 million, operating profit of JPY 260 million and profit attributable to owners of parent of JPY 280 million or JPY 47.40 per basic share.

Latest news about Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2024	Feb. 14	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024	23-08-10	CI
Human Metabolome Technologies, Inc. Announces Year End Dividend for the Year Ended June 30, 2023, Payable on September 7, 2023; Provides Year End Dividend Guidance for the Year Ending June 30, 2024	23-08-10	CI
Human Metabolome Technologies, Inc. Reports Earnings Results for the Nine Months Ended March 31, 2023	23-05-12	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending June 2023	23-05-12	CI
Human Metabolome Technologies, Inc. Provides Dividend Guidance for the Year Ending June 2023	23-05-12	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending June 30, 2023	23-02-14	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023	22-11-11	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023	22-08-10	CI
Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022	22-05-13	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022	22-02-14	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022	21-11-12	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Fourth Quarter Ended June 2021	21-08-13	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022	21-08-13	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Third Quarter Ended March 2021	21-05-12	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Second Quarter Ended December 2020	21-02-12	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2021	21-02-12	CI
Human Metabolome Technologies, Inc. Announces Financial Results for the Quarter Ended September 2020	20-11-11	CI
Human Metabolome Technologies, Inc. Provides Financial Guidance for the Quarter Ending June 2021	20-11-11	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Year Ended June 30, 2020	20-08-14	CI
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending June 30, 2021	20-08-14	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Third Quarter Ended March 2020; Provides Earnings Guidance for the Year Ending June 30, 2020	20-05-08	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Second Quarter Ended December 2019; Provides Consolidated Earnings Guidance for the Year Ending June 30, 2020	20-02-07	CI
Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the Year Ended June 30, 2019; Provides Earnings Guidance for the Fiscal Year Ending June 2020	19-08-14	CI
Human Metabolome Technologies, Inc. Reports Consolidated Earnings Results for the Six Months Ended December 2018	19-02-08	CI

Chart Human Metabolome Technologies, Inc.

Duration

Period

Chart Human Metabolome Technologies, Inc.

More charts

Company Profile

Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q3 2024 Earnings Release

More about the company

	1st Jan change	Capi.
HUMAN METABOLOME TECHNOLOGIES, INC.	+2.34%	24.61M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research